Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
100-Hour Ketamine Infusion for Treatment Resistant Depression
NCT01179009Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2012
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in treatment-resistant depression (TRD) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Montgomery-Asberg Depression Rating Scale at 8 weeks and Clinical Global Impression at 8 weeks. Started Apr 2012; status: completed.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT01179009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01179009.